Abstract
Background People with severe COVID anxiety have significant fears of contagion, physiological symptoms of anxiety in response to a COVID stimuli, and employ safety behaviours which are often in excess of health guidelines and at the expense of other life priorities. The natural course of severe COVID anxiety is not known.
Methods This prospective cohort study followed 285 people with severe COVID anxiety in United Kingdom over 18-months. Descriptive statistics and linear regression models identified factors associated with change in COVID anxiety.
Results Most participants experienced major reductions in COVID anxiety over time (69.8% relative cohort mean decrease; p<0.001), but a quarter of people (23.7%, 95% CI 17.8 to 30.1) continued to worry about COVID every day. Increasing age, being from an ethnic background which conferred greater risk from COVID-19, and the persistence of high levels of health anxiety and depressive symptoms predicted significantly slower improvements in severe COVID anxiety adjusting for other clinical and demographic factors.
Conclusions For most people severe COVID anxiety significantly improves with time. However established interventions treating depression or health anxiety, and targeting older people and people from at-risk minority groups who appear to recover at slower rates, might be clinically indicated in future pandemics.
Highlights
Most people with severe COVID anxiety reported large improvements in symptoms 18-months later.
Levels of co-occurring poor mental health and social functioning also improved for most people.
More than 1 in 10 continued to have severe COVID anxiety symptoms 18 months later.
Age, ethnic background, and high levels of health anxiety and depression predict slower improvements.
People with these risk characteristics could be considered for targeted support.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.isrctn.com/ISRCTN14973494
Funding Statement
This research is supported by funding from the NIHR (National Institute of Health Research UK) Imperial Biomedical Research Centre (WBPP_PA2902). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The sponsor of the study is Imperial College London.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the Leicester Central Research Ethics Committee and Health Regulation Authority in 2020, reference number 20/EM/023. Research was conducted in line with the Declaration of Helsinki 1964, and responses were managed following General Data Protection Regulations. All individuals were required to provide informed consent, by independently reading a participant information sheet before signing an online consent form to participate. Participants received a copy of their consent form.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of Interest: None.
Funding: This research is supported by funding from the NIHR (National Institute of Health Research UK) Imperial Biomedical Research Centre (WBPP_PA2902). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The sponsor of the study is Imperial College London.
Transparency declaration: Authors affirm that this manuscript is an honest, accurate and transparent account of the study as planned.
Availability of data and materials: Data relating to the present analysis are available from the corresponding author on reasonable request. In due course, on completion of analyses, the full COVID Anxiety Project dataset will be made publicly accessible.
Ethics approval and consent to participate: The study received approval from the Leicester Central Research Ethics Committee and Health Regulation Authority in 2020, reference number 20/EM/023. Research was conducted in line with the Declaration of Helsinki 1964, and responses were managed following General Data Protection Regulations. All individuals were required to provide informed consent, by independently reading a participant information sheet before signing an online consent form to participate. Participants received a copy of their consent form.
Data Availability
Data relating to the present analysis are available from the corresponding author on reasonable request. In due course, on completion of analyses, the full COVID Anxiety Project dataset will be made publicly accessible.
